Background Systemic lupus erythematosus (SLE) is a clinically heterogeneous disease in
which the risk of disease is influenced by complex genetic and environmental contributions. …

Background Antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis is a severe
condition encompassing two major syndromes: granulomatosis with polyangiitis (formerly …

Systemic lupus erythematosus (SLE, OMIM 152700) is a complex autoimmune disease that
affects 0.05% of the Western population, predominantly women 1, 2, 3, 4. A number of …

Genome-wide association studies have recently identified at least 15 susceptibility loci for
systemic lupus erythematosus (SLE). To confirm additional risk loci, we selected SNPs from …

Systematic genome-wide studies to map genomic regions associated with human diseases
are becoming more practical. Increasingly, efforts will be focused on the identification of the …

Systemic lupus erythematosus (SLE) is a prototypical autoimmune disease characterized by
production of autoantibodies and complex genetic inheritance 1 , 2 , 3 . In a genome-wide …

Objective Cardiovascular disease with premature atherosclerosis is common in patients with
systemic lupus erythematosus (SLE). We previously identified elevated levels of oxidized …

Systemic lupus erythematosus (SLE) is an autoimmune disease with marked gender and
ethnic disparities. We report a large transancestral association study of SLE using Immunochip …

Objective Rituximab is a monoclonal antibody directed against the CD20 marker of B cells.
Because of its ability to deplete B lymphocytes, it has been suggested that the drug could be …

Herein we investigated how rituximab-induced B cell depletion affected leukocyte subpopulations
and antibody titers in SLE patients. We focused our analysis on time points related to …